Background: A combination of chemotherapy (CT) and radiotherapy (RT) is the treatment base for locally advanced non-small cell lung cancer (NSCLC). The aim of this work was to compare the survival impact of concomitant versus sequential CT and RT for inoperable (stage III) NSCLC.
Original article

IntroductIon
Lung cancer is the most common and deadly tumor worldwide and approximately 1-3 million patients a year die of it 1 . Non-small cell lung cancer accounts for 85% of all new cases diagnosed. Most patients are diagnosed with a non-resectable disease and around 40% in advanced stage 2 . Locally advanced disease (stageIII) is defined as a tumor that exceeds the structures of the lung itself, but without clinical evidence of distant spreading. In the past, radiotherapy was considered the standard therapy in stage IIIA and IIIB, but demonstrated very low survival, poor local control and early development of distant disease. Patients with inoperable stage III treated only with thoracic radiotherapy experienced a median survival of 9-11 months, 2-year survival of 10-20% and 3-year survival of 5-10% 3 . Cure is unlikely in those patients with locally advanced non-small cell lung cancer (NSCLC) who do not receive radical surgery; patients who receive chemotherapy and concomitant radiotherapy have a 3-year survival of approximately 27% 4 . In 1995, a meta-analysis based on individual data from 3,033 patients showed that the combining chemotherapy and radiotherapy gave statistically significant benefit. This difference was greater in those trials that had used platinum treatment in favor of combined chemotherapy and radiotherapy treatment 5 .
Once the benefit of using chemotherapy and radiotherapy was established, the best sequences of treatment became the great unknown. A meta-analysis of 12 clinical trials with 1,921 patients at various stages analyzed the role of chemotherapy based on cisplatin associated with radiotherapy and concluded that the addition of cisplatin to radiotherapy improves survival with absolute benefit of 4% at 2 years (P< 0.02) and the combination of cisplatin and etoposide is more effective than cisplatin alone 6 .
It should be noted that toxicity increases with concurrent treatment, particularly due to grade 3-4 esophagitis. Patients who are undergo concurrent therapy regimens need to be selected using strict criteria to exclude those with weight loss or extensive exposure of lungs to radiotherapy 7 .
Original article A meta-analysis was published to clarify whether concurrent or sequential treatment is better. This included 1,205 patients with 6-years follow-up and demonstrated that concomitant treatment contributed absolute benefit overall survival at 5 years of 4.5% over sequential treatment, but at the cost of increasing toxicity in the form of grade 3-4 esophagitis 8 .
The aim was to compare between sequential and concomitant chemotherapy and radiotherapy in patients with advanced inoperable non-small cell lung cancer. Exclusion criteria included pleural or pericardial effusion, extensive vessel invasion, a diagnosis of smallcell lung cancer, previous treatment with chemotherapy or radiotherapy to lung cancer and impaired renal functions.
PAtIEntS And MEtHodS
This
All eligible patients gave their informed consent prior to the inclusion in the study.
treatment plan:
The sample size was calculated by using the formula of randomized controlled trials. Eighty eligible patients were divided into two groups each group included forty patients. Both groups were balanced in their clinicopathological features.
Group A included forty patients were treated with one cycle of cisplatin 60 mg/m 2 (one hour i.v. infusion) on day 1 plus etoposide 100mg/m 2 /day (30 minutes i.v. infusion) on days 1-3. Radiotherapy was given concomitant with weekly cisplatin 20mg/ m 2 30 minutes infusion on day one of the second cycle chemotherapy for 6 weeks. Radiotherapy was administered 2 hours after completion of chemoradiotherapy infusion. Three cycles of the same chemotherapy every 21 days were administered after completing radiotherapy. All patients received intravenous antiemetic on day 1 with pre-and postchemotherapy hydration.
Radiotherapy consisted of a total dose 60Gy in 30 fractions over 6 weeks (2Gy/fraction for 5 days, each week) using linear accelerator 6MV, twodimensional radiotherapy. The radiation dose was administered to a planning target volume that included computed tomography visible primary tumor (prechemotherapy tumor volume) plus 1cm margins in the transverse diameter and 1.5-2 cm margins in the vertical direction to account for daily setup errors and target motion, it also included elective irradiation of ipsilateral, contralateral hilar, mediastinal, subcarinal and occasionally supraclavicular areas in cases with upper lobe tumors involvement. This is phase I and 40 Gy was delivered by parallel opposing anteroposterior and posteranterior fields. Second phase radiotherapy was delivered to the primary tumor, ipsilateral hilar lymph nodes and 1 cm margin for organ motion during treatment with a direct lateral field had a gantry angle of 90 o , weighted down to 50% to reduce irradiation to the opposite lung. Other fields included anterior 30 o wedge field with a gantry angle O o and a posterior oblique wedge field had a gantry angle of 140 o . Phase II delivered 20 Gy.
Group B included forty patients were treated with three cycle of cisplatin 60mg/m 2 on day 1 and etoposide 100mg/m 2 on days1-3 every 3 weeks followed by the same radiotherapy protocol. Three cycles of cisplatin and etoposide were given after the end of radiotherapy 9 .
Patient evaluation:
All patients underwent a full physical examination, assessment for hematology, renal functions and toxicity. This assessment was conducted every 3 weeks before chemotherapy and again before and after radiation therapy.
Chest x-ray, computed tomography (CT) scan including upper abdomen to assess liver and adrenal gland status were performed before treatment and was repeated 4 weeks after the end of treatment.
Bone scan was performed to all patients before treatment, but brain CT scan was performed if clinically indicated.
Tissue diagnosis was made using biopsy/ brush or bronchial aspirate obtained during fibreoptic bronchoscope.
After completion of study treatment, patients were follow-up every month until disease progression, for a maximum of one year from the date of the last chemotherapy treatment.
Any treatment related side effects recorded and were followed up until resolution.
Tumor response was assessed according to World Health Organization (WHO) criteria 10 . Progression free survival (PFS) was defined as the time from the start of chemotherapy until the date of progression. Overall survival (OS) was determined from the start of chemotherapy to the date of death or last follow-up.
Toxicity was assessed using National Cancer InstituteCommon Toxicity Criteria (NCI-CTC) version 2.0.
Statistical methods:
The primary end points of this study were overall survival (OS) and Progression-free survival (PFS). Secondary end points were response rate and toxicity evaluation of sequential and concomitant chemoradiotherapy. Chi-square test was used to compare differences in distribution of frequencies among various groups of response. P-value 0.05 was considered significant. Overall survival and progression-free survival were calculated using Kaplan-Meier method 11 .
rESuLtS
Eighty patients were included between January 2005 and September 2008. Patients were divided into two groups, group A included forty patients who were treated by concomitant chemoradiotherapy and group B included forty patients who were treated by sequential chemoradiotherapy.
Table (1) shows the baseline patient and tumor characteristics. Both groups were well balanced in their clinico-pathological characteristics except for the percentage of males is significantly higher in group B. Most patients had stage IIIB and squamous cell carcinoma was the commonest histology (55% & 45% in group A& B, respectively). Table ( 2) shows the response rate at study end. There was no significant difference in response between the two groups but partial response was 55% (22/40) in group A which was higher than the partial response rate in group B 40% (16/40). The percentage of patients with progressive disease was 7.5% (3/40) and 25% (10/40) in the group A and B respectively which indicate a better response to concomitant chemoradiotherapy. Tables 4, 5 show the prognostic factors for response in the two groups. The presence of N2-N3 disease was found as a significant adverse prognostic factor.
Safety and toxicity are reported in Table ( 6) , there was no grade 4 toxicity in both groups but grade 3 toxicity was significantly higher in patients treated with concomitant chemoradiotherapy than sequential. Leucopenia is the most common grade 3 hematological adverse events in both groups, occurring in 20% of patients treated with concomitant chemoradiotherpy whish was significantly higher than 5% of patients treated with sequential chemoradiotherapy (P< 0.001). Esophagitis, nausea and vomiting were the most frequent treatment related non-hematological toxicity; both were significantly higher in the concomitant chemoradiotherapy group. The 1-and 2-year survival rates were higher in the concurrent arm (68% and 42%, respectively) than in the sequential arm (48% and 24%, respectively).
The 1-and 2-year progression-free survival was also higher in the concurrent arm (60% and 22%, respectively) than in the sequential arm (32% and 8%, respectively). 13 (59) 9 (41) 5 (50) 5 (50) 1 (20) 4 (80) 0.01*
c-rt
9 (56) 7 (44) 10 (53) 9 (47) 2 (25) 6 ( 
dIScuSSIon
Despite intensive investigation, the prognosis for patients with lung cancer, up to 87% of whom have nonsmall cell lung cancer (NSCLC) at diagnosis, remains poor, with an estimate 5-year survival rate of only 15%
.
The standard treatment of locally advanced unresectable NSCLC is combined chemotherapy and thoracic radiation, based on the results of several randomized phase III trials 13, 14 subsequent trials have demonstrated the superiority of concurrent chemotherapy and radiotherapy over sequential approach at the expense of increased toxicity, in particular sever esophagitis 15, 16 . Concurrent chemoradiotherapy improves overall survival (OS) of patients with locally advanced NSCLC compared with sequential chemoradiotherapy. Platinumbased polychemotherapy is considered the standard treatment. The most active combination in this situation is cisplatin-etoposide which provides a median survival 17, 18 .
In the present study, the partial response rate was not significantly higher in patients treated with concurrent versus sequential chemoradiotherapy (55%vs. 40 %,) but a significant response rate was noted to concomitant chemoradiotherapy than sequential in stage III A and B. This is in agreement with the results of the study done by Fournel et al. 19 who reported a better response rate of (54% vs. 49%) in the concurrent versus sequential chemoradiotherapy. Similar to the current study findings, stage IIIA patients gained particular benefit from concomitant chemoradiotherapy by achieving an overall response rate almost 20% higher than those treated with radiotherapy alone 20 .
These data indicate that concurrent chemoradiotherapy is helpful in improving response and survival than sequential one; this is also seen in previous studies done by Zatloukal et al. 16 and Wang et al. 21 .
The presence of N2-N3 disease was found to be an adverse prognostic factor in the present study (Table 4 ,5) but in the study done by Saynak et al. 9 non-epidermoid histology and Karnofsky Performance Status less than 70 were found as additional prognostic factors.
Median survival times in the current study were 20 months versus 12 months (P<0.001) for patients treated with concurrent versus sequential chemoradiotherapy which is similar to the results of the study done by Crvenkova et al. 22 who reported a median survival 13 months for patients treated with sequential chemoradiotherapy and 22 months for patients treated with concurrent chemoradiotherapy (P<0.001). Conversely, in a study done by Saynak et al. 9 a similar median survival was reported in both groups (14.5 vs. 14.6 months) for patients treated with sequential and concomitant chemoradiotherapy respectively, mostly due to the inclusion of patients with stage III B only in his study.
The 1-and 2-year survival rates were 68% and 42% in the concurrent group and 48% and 24% in the sequential group was noted in the current study which is in agreement with the statistical significant difference in 1-and 2-year survival rates of 73.6% and 39.7% in the concurrent group and 45.4% and 13.7% in the sequential group in a study done by Crvenkova et al. 22 Another study done by fournel et al. 19 also reported a better 2-year survival rates in the concurrent arm than sequential arm(39% vs 26%, respectively).
In the present study, Progression-free survival (PFS) was significantly higher in patients treated with concurrent than sequential chemoradiotherapy (15 vs. 9 months P< 0.001). This is in agreement with the significant difference in DFS in the study done by Crvenkova et al. 22 (17 vs. 9 months P< 0.001).
The 1-year progression-free survival rate was 60% which is lower than the 1-year PFS results reported by Wang et al. 21 (75%), the difference in local control rates may be due to the use of three dimensional conformal radiotherapy in his study.
Both treatments were well tolerated; no grade 4 toxicity was reported in both groups. Notably, little toxicity reported with an increased incidence significantly, especially acute esophagitis and leucopenia, in patients treated with concomitant than sequential chemoradiotherapy. These results were in agreement with results reported by Crevenkova et al. 22 but grade 3 esophagitis in his study was a reason for radiotherapy interruption during conformal threedimensional radiotherapy may be due to the use of high dose chemotherapy concomitantly with radiotherapy.
In an attempt to improve loco-regional control in stage III A-B NSCLC, a three armed randomized trial comparing accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy was tested by Nyman et al. 23 .
Treatment results are quite equal by intensifying the locoregional treatment either by accelerated fractionated radiotherapy or daily or weekly concurrent chemoradiotherpy both in term of survival, toxicity and quality of life.
A phase III randomized study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable NSCLC done by Berghmans et al. 24 . They concluded that consolidation chemoradiotherapy seems less toxic with a better observed response rates and survival.
It remains to be determined whether induction chemotherapy before concurrent chemoradiotherapy or concurrent chemoradiotherpy followed by consolidation chemotherapy is the most effective sequence, but the latter approach has produced a longer survival times. It is important to note that some patients with locally advanced NSCLC do not meet the tumor volume requirements when planning radiotherapy at baseline. Induction chemotherapy might potentially rescue some patients presenting with bulky disease if a policy of encompassing postchemotherapy tumor volume is adopted 20 .
concLuSIon
In conclusion, the addition of chemotherapy to radiation concomitantly prolongs survival than sequential therapy in locally advanced non-small cell lung cancer patients with acceptable adverse event profiles.
rEFErEncES
